We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

BIO-RAD LABORATORIES

Provides full range of instrumentation, reagent kits, software and quality control systems to clinical laboratories. ... read more Featured Products: More products

Download Mobile App




KRAS PCR Screening Kit Detects Seven Mutations in a Single Experiment

By LabMedica International staff writers
Posted on 02 Feb 2015
A research kit designed for use with the latest droplet digital PCR systems is able to detect simultaneously the seven most common KRAS mutations in a single ddPCR experiment. More...


KRAS mutations are found in 90% of pancreatic cancer cases and 30% of colorectal cancer cases, making it a gene of great interest to cancer researchers. The protein product of the normal KRAS (Kirsten rat sarcoma viral oncogene) gene performs an essential function in normal tissue signaling, and its mutation is an essential step in the development of many cancers. A single amino acid substitution is responsible for the activating mutation. The transforming protein that results is implicated in various malignancies, including lung adenocarcinoma, mucinous adenoma, ductal carcinoma of the pancreas, and colorectal carcinoma.

The new Bio-Rad Laboratories, Inc. (Hercules, CA, USA) ddPCR KRAS Screening Multiplex Kit is able to detect and quantify extremely low levels (down to 0.2%) of KRAS mutant DNA in a single assay. Bio-Rad’s ddPCR technology provides an absolute measure of target DNA molecules without the need for a standard curve. This technology enables detection of a single mutant molecule in a background of 2,000 wild-type molecules (0.05% mutation frequency).

The ddPCR KRAS Screening Multiplex Kit is compatible with all of Bio-Rad’s Droplet Digital PCR Systems, including the new AutoDG instrument. AutoDG creates droplets quickly, reproducibly, and reliably. At maximum capacity, the system can generate droplets for 96 wells in less than 45 minutes. The instrument can generate droplets for fluorescent probe-based or EvaGreen dye-based detection. The AutoDG Instrument has its own hood and HEPA filter, reducing contamination so the system can be used on a standard laboratory bench, without the need for a PCR cabinet or cleanroom.

“The KRAS Screening Multiplex Kit delivers a simple yes/no answer as to whether a KRAS mutation exists in smaller samples,” said Dr. Filip Janku of the University of Texas MD Anderson Cancer Center (Houston, USA). “If researchers were to test for the presence of each possible mutation they could end up performing seven to ten separate PCR experiments only to discover the sample was negative. Multiplex kits such as the KRAS Screening Multiplex Kit allow researchers to screen for multiple mutations in a single reaction, saving time and costly resources.”

Related Links:

Bio-Rad Laboratories, Inc.
University of Texas MD Anderson Cancer Center



Platinum Member
Xylazine Immunoassay Test
Xylazine ELISA
Verification Panels for Assay Development & QC
Seroconversion Panels
POCT Fluorescent Immunoassay Analyzer
FIA Go
Gold Member
High-Density Lipoprotein Containing Cholesterol Assay
HDL-c direct FS
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: QIP-MS could predict and detect myeloma relapse earlier compared to currently used techniques (Photo courtesy of Adobe Stock)

Mass Spectrometry-Based Monitoring Technique to Predict and Identify Early Myeloma Relapse

Myeloma, a type of cancer that affects the bone marrow, is currently incurable, though many patients can live for over 10 years after diagnosis. However, around 1 in 5 individuals with myeloma have a high-risk... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Technology

view channel
Image: Ziyang Wang and Shengxi Huang have developed a tool that enables precise insights into viral proteins and brain disease markers (Photo courtesy of Jeff Fitlow/Rice University)

Light Signature Algorithm to Enable Faster and More Precise Medical Diagnoses

Every material or molecule interacts with light in a unique way, creating a distinct pattern, much like a fingerprint. Optical spectroscopy, which involves shining a laser on a material and observing how... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.